References
- Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201–1214.
- Metzgeroth G, Erben P, Martin H, et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2012;26:162–164.
- Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003;100:7830–7835.
- Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFR alpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR alpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009;23:845–851.
- Ohnishi H, Kandabashi K, Maeda Y, et al. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006;134:547–549.
- Score J, Walz C, Jovanovic JV, et al. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient specific genomic DNA fusion junctions. Leukemia 2009;23:332–339.
- Von Bubnoff N, Sandherr M, Schlimok G, et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005;19:286–287.
- Von Bubnoff N, Gorantla SP, Thöne S, et al. The FIP1L1–PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006;107:4970–4971.
- Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008;22:1999–2010.
- Lierman E, Folens C, Stover EH. Sorafenib is a potent inhibitor of FIP1L1-PDGFR alpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006;108:1374–1376.